OTCMKTS:ONCYF - Oncolytics Biotech Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oncolytics Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.74 +0.74 (+∞) (As of 05/24/2018) Add Compare Today's Range$0.74Now: $0.74▼$0.8250-Day Range N/A52-Week Range$0.32Now: $0.74▼$0.90Volume442,324 shsAverage Volume443,150 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.Read More Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ONCYF Previous SymbolNASDAQ:ONCY CUSIPN/A CIKN/A Webhttp://www.oncolyticsbiotech.com/ Phone403-670-7377Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive ONCYF News and Ratings via Email Sign-up to receive the latest news and ratings for ONCYF and its competitors with MarketBeat's FREE daily newsletter. Oncolytics Biotech (OTCMKTS:ONCYF) Frequently Asked Questions How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech, Inc. (OTCMKTS:ONCYF) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. View Oncolytics Biotech's earnings history. Has Oncolytics Biotech been receiving favorable news coverage? Media headlines about ONCYF stock have been trending somewhat negative on Tuesday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncolytics Biotech earned a news impact score of -1.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutOncolytics Biotech. Who are some of Oncolytics Biotech's key competitors? Some companies that are related to Oncolytics Biotech include Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Immune Therapeutics (IMUN), Intec Pharma (NTEC), Mereo BioPharma Group (MREO), Myrexis (MYRX) and NeuroVive Pharmaceutical (NEVPF). What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONC), Abraxas Petroleum (AXAS), Catalyst Pharmaceuticals (CPRX), Nabriva Therapeutics (NBRV), Agenus (AGEN), Cytori Therapeutics (CYTX), Inovio Pharmaceuticals (INO), SciClone Pharmaceuticals (SCLN), ZIOPHARM Oncology (ZIOP) and Spark Networks (LOV). Who are Oncolytics Biotech's key executives? Oncolytics Biotech's management team includes the following people: Dr. Matthew C. Coffey, Pres, CEO & DirectorMr. Kirk J. Look, Chief Financial OfficerMr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 51)Mr. Michael Moore, VP of Investor Relations & Corp. CommunicationsDr. Daniel Douglas Von Hoff M.D., F.A.C.P., Consultant (Age 70) What is Oncolytics Biotech's stock symbol? Oncolytics Biotech trades on the OTCMKTS under the ticker symbol "ONCYF." What is Oncolytics Biotech's stock price today? One share of ONCYF stock can currently be purchased for approximately $0.74. What is Oncolytics Biotech's official website? The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com/. How can I contact Oncolytics Biotech? Oncolytics Biotech's mailing address is 1167 Kensington Crescent NW Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected] MarketBeat Community Rating for Oncolytics Biotech (OTCMKTS ONCYF)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 129 (Vote Outperform)Underperform Votes: 110 (Vote Underperform)Total Votes: 239MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONCYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCYF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: What are convertible shares?